Janelle DAlvise - ACST Old President CEO
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
CEO
Ms. Janelle DAlvise serves as President, Chief Executive Officer, Director of the Company. She has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Until recently, Ms. DAlvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. DAlvise was the CEO of the Sidney Kimmel Cancer Center, a drug discovery research institute. From 1995, she was also the CoFounder and Executive VPCOO of Metrika Inc., and in 1999 was the CoFounderPresidentCEO Chairman of NuGEN, Inc. Ms. DAlvise built both companies from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to 1995, Ms. DAlvise was a VP of Drug Development at SyntexRoche and Business Unit Director of their Pain and Inflammation business, and also VP of Commercial Operations at SYVA,, and began her career with Diagnostic Products Corporation since 2017.
| Age | 69 |
| Tenure | 8 years |
| Phone | 818-839-4378 |
| Web | https://www.acastipharma.com |
ACST Old Management Efficiency
The company has return on total asset (ROA) of (0.1162) % which means that it has lost $0.1162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1856) %, meaning that it created substantial loss on money invested by shareholders. ACST Old's management efficiency ratios could be used to measure how well ACST Old manages its routine affairs as well as how well it operates its assets and liabilities.ACST Old currently holds 11.56 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ACST Old has a current ratio of 10.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ACST Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 5 records | CEO Age | ||
| Lisa Conte | Jaguar Animal Health | 66 | |
| Rachelle Jacques | Akari Therapeutics PLC | 53 | |
| Samir MD | Akari Therapeutics PLC | 56 | |
| Shankar MBA | Ocugen Inc | 61 | |
| Teofilo MBA | Pulmatrix | 54 | |
Management Performance
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 |
ACST Old Leadership Team
Elected by the shareholders, the ACST Old's board of directors comprises two types of representatives: ACST Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACST. The board's role is to monitor ACST Old's management team and ensure that shareholders' interests are well served. ACST Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ACST Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Kottayil, Chief US | ||
| Robert CPA, Principal Officer | ||
| Prashant Kohli, Chief Officer | ||
| Amresh Kumar, VP Management | ||
| Janelle DAlvise, President CEO | ||
| Yves Lachance, VP Compliance | ||
| Carrie DAndrea, VP Operations | ||
| Pierre MD, COO CoFounder | ||
| Christine Pelletier, Director HR |
ACST Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ACST Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 | |||
| Current Valuation | 11.17 M | |||
| Shares Outstanding | 10.14 M | |||
| Shares Owned By Insiders | 38.39 % | |||
| Shares Owned By Institutions | 21.22 % | |||
| Number Of Shares Shorted | 154.19 K | |||
| Price To Earning | 15.34 X | |||
| Price To Book | 0.58 X | |||
| Price To Sales | 208.39 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in ACST Stock
If you are still planning to invest in ACST Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ACST Old's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |